Rene v Val26 Apr 2019 11:29
The positive side of Biotech - Rene up 23%
Negative side of Biotech - Valiex F@@@C down 23%
It's all about management... Rene - RNS today
("ReNeuron" or the "Company")
Clinical update and conference presentation
Latest results show sustained and further improvement in vision at 60 and 120 days in first patient cohort of Phase 2a study of hRPC cell therapy in retinitis pigmentosa
ReNeuron Group plc (AIM: RENE), a global leader in the development of cell-based therapeutics, is pleased to announce updated positive preliminary data in the Company's ongoing Phase 1/2a clinical trial of its human retinal progenitor cell (hRPC) therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP). All three subjects in the first cohort of the Phase 2a element of the study have demonstrated a sustained and further improvement in vision compared with their pre-treatment baseline.
VAL - RNS today
Subscription, Convertible Funds and Warrant Issue
Fri, 26th Apr 2019 07:00
RNS Number : 1676X
ValiRx PLC
26 April 2019
Don't need to post more information... 120 days.... RENE v VAL 334543543 days